NHEJ1的遗传变异和相关的DNA修复障碍:表型异质性和与发育不良骨髓增生异常综合征和家族性血液恶性肿瘤易感性的联系

IF 3 3区 医学 Q2 HEMATOLOGY
Mahmoud I. Elbadry, Elsayed Abdelkreem, Ahmed Tawfeek, Go Hun Seo, Shereen Philip Aziz
{"title":"NHEJ1的遗传变异和相关的DNA修复障碍:表型异质性和与发育不良骨髓增生异常综合征和家族性血液恶性肿瘤易感性的联系","authors":"Mahmoud I. Elbadry,&nbsp;Elsayed Abdelkreem,&nbsp;Ahmed Tawfeek,&nbsp;Go Hun Seo,&nbsp;Shereen Philip Aziz","doi":"10.1007/s00277-025-06257-6","DOIUrl":null,"url":null,"abstract":"<div><p>This study investigates the burden, phenotypes, progression, and outcomes of familial hematological malignancies (FHM) through clinical evaluation, gene panel testing, and whole exome sequencing, highlighting the significance of identifying genetic causes for personalized treatment. Over six years, 357 patients initially diagnosed with bone marrow failure (BMF) were evaluated, with 152 patients lacking identifiable causes undergoing further analysis. Among these, 53 (34.9%) exhibited features of inherited BMF syndromes, and 13 (24.5%) developed FHM. In a separate cohort of 27 patients with inherited immunodeficiency disorders, 8 (29.6%) developed FHM associated with <i>NHEJ1</i> or <i>LYST</i> variants, underscoring the familial clustering of hematologic disorders. Notably, 6 of 7 patients from the same family (family-1) with homozygous <i>NHEJ1</i> variants progressed to secondary myelodysplastic syndrome (sMDS), acute myeloid leukemia (AML), or lymphoma. Among 780 patients diagnosed with hematological malignancies during the study period, 45 (5.8%) were confirmed to have FHM, with 33 patients enrolled for detailed analysis. Of these, 16 (48.5%) had DNA-repair deficiencies (DNA-RD), including eight with Fanconi anemia, six with <i>NHEJ1</i> variants, and two with <i>BRCA2</i> mutations. The remaining 17 patients presented conditions such as familial myeloproliferative neoplasms, dyskeratosis congenita (DC) [<i>TERT</i>, <i>DKC1</i> variants], and Chediak-Higashi syndrome. Two siblings (family-3) with a rare <i>TERT</i> variant and a unique DC phenotype developed sMDS after prolonged BMF. Patients with DNA-RD were younger and exhibited higher rates of growth failure, recurrent infections, and endocrinopathies. These cases frequently progressed to sMDS or AML. A comparative analysis of 319 individuals with DNA double-strand break repair deficiencies revealed a 45% frequency of hematological malignancies. Lymphoma was most common in Nijmegen breakage syndrome (79.4%) while MDS/AML was prevalent in Cernunnos deficiency (66.6%). The findings emphasize the importance of early diagnosis, genetic testing, and personalized management, including timely transplantation, to improve outcomes in FHM. This research underscores the need for clinical awareness and surveillance to facilitate timely interventions and mitigate disease progression.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"104 3","pages":"1633 - 1653"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-025-06257-6.pdf","citationCount":"0","resultStr":"{\"title\":\"Genetic variants in NHEJ1 and related DNA repair disorders: insights into phenotypic heterogeneity and links to hypoplastic myelodysplastic syndromes and familial hematological malignancies susceptibility\",\"authors\":\"Mahmoud I. Elbadry,&nbsp;Elsayed Abdelkreem,&nbsp;Ahmed Tawfeek,&nbsp;Go Hun Seo,&nbsp;Shereen Philip Aziz\",\"doi\":\"10.1007/s00277-025-06257-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This study investigates the burden, phenotypes, progression, and outcomes of familial hematological malignancies (FHM) through clinical evaluation, gene panel testing, and whole exome sequencing, highlighting the significance of identifying genetic causes for personalized treatment. Over six years, 357 patients initially diagnosed with bone marrow failure (BMF) were evaluated, with 152 patients lacking identifiable causes undergoing further analysis. Among these, 53 (34.9%) exhibited features of inherited BMF syndromes, and 13 (24.5%) developed FHM. In a separate cohort of 27 patients with inherited immunodeficiency disorders, 8 (29.6%) developed FHM associated with <i>NHEJ1</i> or <i>LYST</i> variants, underscoring the familial clustering of hematologic disorders. Notably, 6 of 7 patients from the same family (family-1) with homozygous <i>NHEJ1</i> variants progressed to secondary myelodysplastic syndrome (sMDS), acute myeloid leukemia (AML), or lymphoma. Among 780 patients diagnosed with hematological malignancies during the study period, 45 (5.8%) were confirmed to have FHM, with 33 patients enrolled for detailed analysis. Of these, 16 (48.5%) had DNA-repair deficiencies (DNA-RD), including eight with Fanconi anemia, six with <i>NHEJ1</i> variants, and two with <i>BRCA2</i> mutations. The remaining 17 patients presented conditions such as familial myeloproliferative neoplasms, dyskeratosis congenita (DC) [<i>TERT</i>, <i>DKC1</i> variants], and Chediak-Higashi syndrome. Two siblings (family-3) with a rare <i>TERT</i> variant and a unique DC phenotype developed sMDS after prolonged BMF. Patients with DNA-RD were younger and exhibited higher rates of growth failure, recurrent infections, and endocrinopathies. These cases frequently progressed to sMDS or AML. A comparative analysis of 319 individuals with DNA double-strand break repair deficiencies revealed a 45% frequency of hematological malignancies. Lymphoma was most common in Nijmegen breakage syndrome (79.4%) while MDS/AML was prevalent in Cernunnos deficiency (66.6%). The findings emphasize the importance of early diagnosis, genetic testing, and personalized management, including timely transplantation, to improve outcomes in FHM. This research underscores the need for clinical awareness and surveillance to facilitate timely interventions and mitigate disease progression.</p></div>\",\"PeriodicalId\":8068,\"journal\":{\"name\":\"Annals of Hematology\",\"volume\":\"104 3\",\"pages\":\"1633 - 1653\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s00277-025-06257-6.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s00277-025-06257-6\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00277-025-06257-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本研究通过临床评估、基因面板检测和全外显子组测序研究家族性血液学恶性肿瘤(FHM)的负担、表型、进展和结局,强调了确定遗传原因对个性化治疗的重要性。在6年多的时间里,对357名最初诊断为骨髓衰竭(BMF)的患者进行了评估,其中152名患者缺乏可识别的原因,正在进行进一步分析。其中53例(34.9%)表现出遗传性BMF综合征的特征,13例(24.5%)表现为FHM。在27例遗传性免疫缺陷疾病患者的单独队列中,8例(29.6%)发生了与NHEJ1或LYST变异相关的FHM,强调了血液疾病的家族聚集性。值得注意的是,来自同一家族(家族1)的7例纯合子NHEJ1变异体患者中有6例进展为继发性骨髓增生异常综合征(sMDS)、急性髓性白血病(AML)或淋巴瘤。在研究期间诊断为血液系统恶性肿瘤的780例患者中,45例(5.8%)确诊为FHM,其中33例患者入组进行详细分析。其中16人(48.5%)有dna修复缺陷(DNA-RD),包括8人患有范可尼贫血,6人患有NHEJ1变异,2人患有BRCA2突变。其余17例患者表现为家族性骨髓增生性肿瘤、先天性角化不良(DC) [TERT, DKC1变异体]和Chediak-Higashi综合征。具有罕见TERT变异和独特DC表型的两个兄弟姐妹(家族3)在长时间BMF后发生sMDS。DNA-RD患者较年轻,表现出较高的生长衰竭、复发性感染和内分泌病变的发生率。这些病例经常发展为多发性硬化或急性髓性白血病。一项对319名DNA双链断裂修复缺陷患者的比较分析显示,血液恶性肿瘤的发生率为45%。奈亨破裂综合征以淋巴瘤最为常见(79.4%),Cernunnos缺乏症以MDS/AML最为常见(66.6%)。研究结果强调了早期诊断、基因检测和个性化管理(包括及时移植)对改善FHM预后的重要性。这项研究强调了临床意识和监测的必要性,以促进及时干预和减缓疾病进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Genetic variants in NHEJ1 and related DNA repair disorders: insights into phenotypic heterogeneity and links to hypoplastic myelodysplastic syndromes and familial hematological malignancies susceptibility

This study investigates the burden, phenotypes, progression, and outcomes of familial hematological malignancies (FHM) through clinical evaluation, gene panel testing, and whole exome sequencing, highlighting the significance of identifying genetic causes for personalized treatment. Over six years, 357 patients initially diagnosed with bone marrow failure (BMF) were evaluated, with 152 patients lacking identifiable causes undergoing further analysis. Among these, 53 (34.9%) exhibited features of inherited BMF syndromes, and 13 (24.5%) developed FHM. In a separate cohort of 27 patients with inherited immunodeficiency disorders, 8 (29.6%) developed FHM associated with NHEJ1 or LYST variants, underscoring the familial clustering of hematologic disorders. Notably, 6 of 7 patients from the same family (family-1) with homozygous NHEJ1 variants progressed to secondary myelodysplastic syndrome (sMDS), acute myeloid leukemia (AML), or lymphoma. Among 780 patients diagnosed with hematological malignancies during the study period, 45 (5.8%) were confirmed to have FHM, with 33 patients enrolled for detailed analysis. Of these, 16 (48.5%) had DNA-repair deficiencies (DNA-RD), including eight with Fanconi anemia, six with NHEJ1 variants, and two with BRCA2 mutations. The remaining 17 patients presented conditions such as familial myeloproliferative neoplasms, dyskeratosis congenita (DC) [TERT, DKC1 variants], and Chediak-Higashi syndrome. Two siblings (family-3) with a rare TERT variant and a unique DC phenotype developed sMDS after prolonged BMF. Patients with DNA-RD were younger and exhibited higher rates of growth failure, recurrent infections, and endocrinopathies. These cases frequently progressed to sMDS or AML. A comparative analysis of 319 individuals with DNA double-strand break repair deficiencies revealed a 45% frequency of hematological malignancies. Lymphoma was most common in Nijmegen breakage syndrome (79.4%) while MDS/AML was prevalent in Cernunnos deficiency (66.6%). The findings emphasize the importance of early diagnosis, genetic testing, and personalized management, including timely transplantation, to improve outcomes in FHM. This research underscores the need for clinical awareness and surveillance to facilitate timely interventions and mitigate disease progression.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annals of Hematology
Annals of Hematology 医学-血液学
CiteScore
5.60
自引率
2.90%
发文量
304
审稿时长
2 months
期刊介绍: Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信